The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Nivolumab BMS (nivolumab). Nivolumab BMS can be used to treat adult patients with a type of lung cancer called squamous non-small cell lung cancer (NSCLC), when the disease is advanced, and has already been treated with chemotherapy. It is the first immunotherapy medicine recommended for approval for squamous NSCLC in the European Union (EU).

In April 2015, EMA recommended for approval another nivolumab-containing medicine, Opdivo, for the treatment of patients with advanced (unresectable or metastatic) melanoma.

For more details, go to: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/05/news_detail_002335.jsp&mid=WC0b01ac058004d5c1